235 related articles for article (PubMed ID: 27939638)
1. Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes.
Shen Q; Cheng F; Song H; Lu W; Zhao J; An X; Liu M; Chen G; Zhao Z; Zhang J
Am J Hum Genet; 2017 Jan; 100(1):5-20. PubMed ID: 27939638
[TBL] [Abstract][Full Text] [Related]
2. AlloDriver: a method for the identification and analysis of cancer driver targets.
Song K; Li Q; Gao W; Lu S; Shen Q; Liu X; Wu Y; Wang B; Lin H; Chen G; Zhang J
Nucleic Acids Res; 2019 Jul; 47(W1):W315-W321. PubMed ID: 31069394
[TBL] [Abstract][Full Text] [Related]
3. Allosteric Methods and Their Applications: Facilitating the Discovery of Allosteric Drugs and the Investigation of Allosteric Mechanisms.
Lu S; Shen Q; Zhang J
Acc Chem Res; 2019 Feb; 52(2):492-500. PubMed ID: 30688063
[TBL] [Abstract][Full Text] [Related]
4. Tissue-Specific Signaling Networks Rewired by Major Somatic Mutations in Human Cancer Revealed by Proteome-Wide Discovery.
Zhao J; Cheng F; Zhao Z
Cancer Res; 2017 Jun; 77(11):2810-2821. PubMed ID: 28364002
[TBL] [Abstract][Full Text] [Related]
5. DeepAlloDriver: a deep learning-based strategy to predict cancer driver mutations.
Song Q; Li M; Li Q; Lu X; Song K; Zhang Z; Wei J; Zhang L; Wei J; Ye Y; Zha J; Zhang Q; Gao Q; Long J; Liu X; Lu X; Zhang J
Nucleic Acids Res; 2023 Jul; 51(W1):W129-W133. PubMed ID: 37078611
[TBL] [Abstract][Full Text] [Related]
6. Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach.
Zhao J; Cheng F; Wang Y; Arteaga CL; Zhao Z
Mol Cell Proteomics; 2016 Feb; 15(2):642-56. PubMed ID: 26657081
[TBL] [Abstract][Full Text] [Related]
7. Unraveling allosteric landscapes of allosterome with ASD.
Liu X; Lu S; Song K; Shen Q; Ni D; Li Q; He X; Zhang H; Wang Q; Chen Y; Li X; Wu J; Sheng C; Chen G; Liu Y; Lu X; Zhang J
Nucleic Acids Res; 2020 Jan; 48(D1):D394-D401. PubMed ID: 31665428
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and architecture of posttranscriptionally impaired synonymous mutations in 8,320 genomes across 22 cancer types.
Teng H; Wei W; Li Q; Xue M; Shi X; Li X; Mao F; Sun Z
Nucleic Acids Res; 2020 Feb; 48(3):1192-1205. PubMed ID: 31950163
[TBL] [Abstract][Full Text] [Related]
9. Mutational landscape of RNA-binding proteins in human cancers.
Neelamraju Y; Gonzalez-Perez A; Bhat-Nakshatri P; Nakshatri H; Janga SC
RNA Biol; 2018 Jan; 15(1):115-129. PubMed ID: 29023197
[TBL] [Abstract][Full Text] [Related]
10. AlloMAPS: allosteric mutation analysis and polymorphism of signaling database.
Tan ZW; Tee WV; Guarnera E; Booth L; Berezovsky IN
Nucleic Acids Res; 2019 Jan; 47(D1):D265-D270. PubMed ID: 30365033
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule binding sites to explore protein-protein interactions in the cancer proteome.
Xu D; Jalal SI; Sledge GW; Meroueh SO
Mol Biosyst; 2016 Oct; 12(10):3067-87. PubMed ID: 27452673
[TBL] [Abstract][Full Text] [Related]
12. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
[TBL] [Abstract][Full Text] [Related]
13. Whole-exome sequencing to identify novel somatic mutations in squamous cell lung cancers.
Zheng CX; Gu ZH; Han B; Zhang RX; Pan CM; Xiang Y; Rong XJ; Chen X; Li QY; Wan HY
Int J Oncol; 2013 Sep; 43(3):755-64. PubMed ID: 23799614
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.
Hu R; Huffman KE; Chu M; Zhang Y; Minna JD; Yu Y
J Proteome Res; 2016 Feb; 15(2):477-86. PubMed ID: 26736068
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Analysis Reveals Cancer Missense Mutations Target Protein Interaction Interfaces.
Engin HB; Kreisberg JF; Carter H
PLoS One; 2016; 11(4):e0152929. PubMed ID: 27043210
[TBL] [Abstract][Full Text] [Related]
16. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: An effort to explore new drug targets.
Veldore VH; Patil S; Satheesh CT; Shashidhara HP; Tejaswi R; Prabhudesai SA; Krishnamoorthy N; Hazarika D; Naik R; Rao RM; Ajai Kumar BS
Indian J Cancer; 2015; 52(2):243-8. PubMed ID: 26853422
[TBL] [Abstract][Full Text] [Related]
17. Biophysical simulations and structure-based modeling of residue interaction networks in the tumor suppressor proteins reveal functional role of cancer mutation hotspots in molecular communication.
Verkhivker GM
Biochim Biophys Acta Gen Subj; 2019 Jan; 1863(1):210-225. PubMed ID: 30339916
[TBL] [Abstract][Full Text] [Related]
18. The energetic and allosteric landscape for KRAS inhibition.
Weng C; Faure AJ; Escobedo A; Lehner B
Nature; 2024 Feb; 626(7999):643-652. PubMed ID: 38109937
[TBL] [Abstract][Full Text] [Related]
19. A Gene Gravity Model for the Evolution of Cancer Genomes: A Study of 3,000 Cancer Genomes across 9 Cancer Types.
Cheng F; Liu C; Lin CC; Zhao J; Jia P; Li WH; Zhao Z
PLoS Comput Biol; 2015 Sep; 11(9):e1004497. PubMed ID: 26352260
[TBL] [Abstract][Full Text] [Related]
20. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
